Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLO I: single-dose oritavancin versus vancomycin for acute bacterial skin and skin structure infection
2010-021424-94Phase 3Completed
- Sponsor
- The Medicines Company
- Start
- Dec 2010
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute bacterial skin and skin structure infection (ABSSSI) and bacterial wound infection comparing Single-dose oritavancin with Vancomycin for 7 to 10 days (2 arms). Primary endpoint: Early clinical response at 48 to 72 hours. Started Dec 2010; status: completed.
02
Drugs
oritavancinvancomycin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)bacterial wound infection
Beyond the preview
Go deeper on 2010-021424-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021424-94.